European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading

MT Newswires Live12-17

European equities traded in the US as American depositary receipts started the week off higher late Monday morning, rising 0.32% to 1,343.34 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical companies argenx (ARGX) and Grifols (GRFS), which rose 4.3% and 3.9% respectively. They were followed by medical device maker EDAP TMS (EDAP) and pharmaceutical company Ascendis Pharma (ASND), which increased 3.1% and 2.7% respectively.

The decliners from continental Europe were led by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which fell 18% and 3.1% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and petroleum refiner Equinor (EQNR), which were down 2.8% and 2.4% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company Bicycle Therapeutics (BCYC) and biotech firm Autolus Therapeutics (AUTL), which advanced 8.6% and 5% respectively. They were followed by biopharmaceutical companies Verona Pharma (VRNA) and Amarin (AMRN), which were up 4.6% and 2.4% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company Mereo BioPharma Group (MREO) and biotech firm Trinity Biotech (TRIB), which dropped 3.7% and 2.2% respectively. They were followed by oil and gas company BP (BP) and insurance company Prudential (PUK), which lost 2.1% and 1.1% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment